Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elmex CARIES PROTECTION dental rinse is a fluoride-based oral solution developed by GABA International (now a subsidiary of Colgate-Palmolive) for the prevention of dental caries. The formulation contains a combination of amine fluoride (olaflur) and sodium fluoride, providing a total fluoride concentration of 250 ppm. Its primary mechanism of action involves the interaction of fluoride ions with the hydroxyapatite in tooth enamel, facilitating the formation of a calcium fluoride-like layer that enhances remineralization and increases resistance to acid-induced demineralization. This alcohol-free rinse is particularly indicated for daily use in individuals at high risk for tooth decay, including those undergoing orthodontic treatment with fixed appliances. It is intended as a complement to daily tooth brushing and is not recommended for children under 6 years of age.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on olaflur + sodium fluoride.